echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Olaparib in metastatic castration-resistant prostate cancer with ctDNA BRCA/ATM variants

    Clin Cancer Res: Olaparib in metastatic castration-resistant prostate cancer with ctDNA BRCA/ATM variants

    • Last Update: 2022-11-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Metastatic castration-resistant prostate cancer (mCRPC) is a molecularly heterogeneous disorder with a poor
    prognosis.
    About 20-30% of patients carry harmful variants in DNA damage repair genes, including those that directly or indirectly play a role in the homologous recombinant repair (HRR) pathway
    .

     

     

    The Phase 3 PROfound study evaluated the efficacy
    of olaparib compared to abiraterone or enzalutamide (control) in patients with metastatic castration-resistant prostate cancer carrying HRR gene variants.
    The results of an exploratory analysis using ctDNA testing as an additional method to identify patients with mCRPC with HRR gene variants are candidates for olaparib therapy
    .

     

    The researchers retrospectively analyzed BRCA1, BRCA2, and ATM variants
    in the plasma ctDNA of patients in the PROfound trial.
    Only patients in Cohort A (those with positive BRCA/ATM variant validated by tissue testing)
    were assessed.
    The investigators compared the clinical prognosis of patients in the ctDNA subgroup and cohort A, including radiographic progression-free survival (rPFS).

     


    A cohort ctDNA subgroup rPFS in two treatment groups

     

    Of the 181 (73.
    9%) patients in Cohort A, 139 (76.
    8%) had test results, of which 111 (79.
    9%) were detected as carrying the BRCA/ATM variant
    .
    Of the patients carrying the BRCA/ATM variant, 73 received olaparib and 38 received control
    .
    The baseline demographics and characteristics and HRR variation rates of patients carrying BRCA/ATM variants were comparable
    to those in Cohort A's intention-to-treat population.

     


    rPFS and OS in the A cohort ctDNA subgroup and the A cohort in the intention-to-treat population

     

    Compared with the control group, the rPFS was longer in the olaparib group (median rPFS: 7.
    4 vs 3.
    5 months; Risk ratio [HR] 0.
    33, p<0.
    0001), consistent with Cohort A's intention-to-treat population (HR 0.
    34).

     

    In summary, ctDNA testing may be a suitable option
    for identifying patients with mCRPC with BRCA/ATM variants who may benefit from olaparib when tumor tissue testing is not feasible or fails.

     

    Original source:

    Nobuaki Matsubara, Johann de Bono, David Olmos, et al.
    Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA.
    Clin Cancer Res 2022; https://doi.
    org/10.
    1158/1078-0432.
    CCR-21-3577

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.